The Net Clinical Benefit of Rivaroxaban Compared to Low-Molecular-Weight Heparin in the Treatment of Cancer-Associated Thrombosis: Systematic Review and Meta-Analysis

Cancer-associated thrombosis (CAT) carries significant morbidity and mortality. Low-molecular-weight heparin (LMWH) remains the standard of care, with recent systematic studies suggesting the efficacy and safety of rivaroxaban in the treatment of CAT. Uncertainty, however, remains regarding rivaroxa...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Clin Appl Thromb Hemost
Glavni autori: Mohamed, Mouhand F. H., ElShafei, Mohamad Nabil, Ahmed, Mohamed Badie, Abdalla, Lina O., Ahmed, Israa, Elzouki, Abdel-Naser, Danjuma, Mohammed ibn-mas’ud
Format: Artigo
Jezik:Inglês
Izdano: SAGE Publications 2021
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7930650/
https://ncbi.nlm.nih.gov/pubmed/33651658
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1076029620940046
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items